Colorectal: Archives News of the month
Does adjuvant chemotherapy result in poorer health-related quality of life among colorectal cancer patients? A longitudinal multisite observational study in Singapore
Colorectal 5 min.
Colorectal cancer (CRC) is one of the most prevalent cancers, with nearly two million incident cases globally in 2018 [1]. Surgery remains the primary treatment for most patients presenting with potentially curable CRC [2, 3]. Following surgery, patients with more advanced cancers usually undergo adjuvant...
Analysis of extracellular vesicles of frequently used colorectal cancer cell lines
Colorectal 7 min.
Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide, with an estimated 1.93 million new cases diagnosed in 2022 alone [1]. This statistic stresses the urgent need for the development of more effective diagnostic and therapeutic strategies, and also for a deeper...
Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
Colorectal 5 min.
Colorectal cancer (CRC) is the leading cause of death worldwide and the most commonly diagnosed gastrointestinal cancer [1, 2]. Approximately 10% of CRC cases have a BRAF mutation, with the V600E mutation being the most common type. CRCs with BRAF mutations are generally associated with a poor prognosis...
Gender-specific differences in factors influencing supportive care needs in colorectal cancer patients
Colorectal 4 min.
The latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020 showed that the number of new colorectal cancer (CRC) cases in the world amounted to 1.93 million and the number of CRC deaths was 0.94 million [1]....
Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
Colorectal 5 min.
Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related morbidity and mortality worldwide [1]. The combination of fluorouracil, oxaliplatin, and/or irinotecan (CAPOX/FOLFOX/FOLFIRI) with bevacizumab is a first-line standard treatment option for mCRC patients with RAS mutation...
